Grade @ and @ adverse events were more common with combination therapy than with monotherapy , including fatigue ( @ patients in the cediranib plus olaparib group vs five patients in the olaparib monotherapy group ) , diarrhoea ( ten vs none ) , and hypertension ( @ vs none ) .